Collaboration was the buzzword at the annual conference of the medicine developers based in Ireland last week where, among the speakers, was deputy director of the National Centre for Pharmacoeconomics (NCPE) Dr Lesley Tilson.
The Irish Pharmaceutical Healthcare Association (Ipha) has spent much of the past decade at loggerheads with the NCPE, whose job it is to vet medicines looking to enter the Irish market and see whether they provide value for money.
Part of that has been down to what the pharma groups have at times argued is a flawed assessment model that fails to appreciate the value, particularly of medicines targeting small patient populations but a more recurring complaint has been the length of time it takes medicine to get through the approvals process in Ireland compared to other European countries.
Should banks be on the hook for access to cash into the future here?
But all that was forgotten even before Minister for Health Stephen Donnelly told delegates he was adding 34 new staff to the team policing drug approvals.
Yes, the US has higher income per capita than Europe, but what is the real measure of a wealthy nation?
Your work questions answered: Can bonuses be deducted pro-rata during a maternity leave?
China the key for tech’s raw materials whether Trump likes it or not
Belfast-based watchmaker Nomadic moves with the times to reinvent retail experience
Well, maybe not quite forgotten. Tilson was sitting on a panel with Amgen country head, Caitríona Duggan, who also serves as chairwoman of Ipha’s market access committee. And despite the oft-repeated talk of collaboration and shared purpose, both were not averse to scoring points for their respective “sides”.
Consultant medical oncologist Michael McCarthy, who works entirely in the public health system at University Hospital, Galway noted on the same panel that between 30 and 40 per cent of cancer drugs licensed by the European Medicines Agency (EMA) never even go before the NCPE Irish approvals and pricing system.
Duggan followed that up by declaring that 27 per cent of medicines developed by Ipha members do not get submitted to the system even as she welcomed the new era of “discussion, dialogue and shared purpose”.
Tilson was not to be bowed, telling delegates that timelines depended on all stakeholders, including industry.
“We cannot reimburse something if there is no application,” she said, adding that, in 2023, “only 12 per cent of submissions were made within the first month of [EMA] marketing authorisation”. Touché.
- Sign up for Business push alerts and have the best news, analysis and comment delivered directly to your phone
- Find The Irish Times on WhatsApp and stay up to date
- Our Inside Business podcast is published weekly – Find the latest episode here
